TC Biopharm (Holdings) Plc (TCBP) Financial Analysis & Valuation | Quarter Chart
TC Biopharm (Holdings) Plc (TCBP)
TCBPPrice: $0.5
Fair Value: 🔒
🔒score
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniSti... more
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immuno... more
Description
Shares
| Market Cap | $256,496 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | Bryan Leland Kobel |
| IPO Date | 2022-02-11 | CAGR | — |
| Employees | 41 | Website | www.tcbiopharm.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
TCBP chart loading...
Fundamentals
Technicals
| Enterprise Value | $685.64M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.09 |
| P/CF Ratio | -0.02 | P/FCF Ratio | -0.02 |
| EPS | $-4794.42 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -3.92% | ROA | -0.66% |
| ROCE | -3.41% | Current Ratio | 1.2 |
| Quick Ratio | 1.2 | Cash Ratio | 0.52 |
| Debt/Equity | 0.67 | Interest Coverage | — |
| Altman Z Score | -14.68 | Piotroski Score | 2 |